Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Hope, DeCederfelt"'
Autor:
Sumana Chakravarty, Eric R. James, Stephen L. Hoffman, Lei K. Ding, Jillian Neal, Charles Wyatt, Sahand Kalhori, Anita Manoj, Alemush Imeru, Omely Marte-Salcedo, Sangeeta N. Bhatia, Hope Decederfelt, David M. Cook, Agnes Mwakingwe-Omari, Martha Nason, Jen C. C. Hume, Sara A. Healy, Aarti Kolluri, Natasha Kc, Ijeoma Ikpeama, B. Kim Lee Sim, Peter F. Billingsley, Sean C. Murphy, L. W. Preston Church, Jihyun E. Jeon, Sandra March, Grace K. Lee, Irfan Zaidi, Jacob Raiten, Junhui Duan, Anusha Gunasekera, Thomas L. Richie, Tooba Murshedkar, Jacquelyn Lane, Patrick E. Duffy, Charles Anderson
Publikováno v:
Nature. 595:289-294
The global decline in malaria has stalled1, emphasizing the need for vaccines that induce durable sterilizing immunity. Here we optimized regimens for chemoprophylaxis vaccination (CVac), for which aseptic, purified, cryopreserved, infectious Plasmod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5683981db2e900df72762416f20eb4b7
https://doi.org/10.1038/s41586-021-03684-z
https://doi.org/10.1038/s41586-021-03684-z
Autor:
Jonathan P. Renn, Raul Herrera, Bruce J. Swihart, Hope Decederfelt, Charlotte V. Hobbs, David L. Narum, Erin E. Gabriel, Lynn Lambert, Patrick E. Duffy, Nicholas J. MacDonald, Charles Anderson, Kelly M. Rausch, Agnes Mwakingwe, Yimin Wu, Camila H. Coelho, Irfan Zaidi, Puthupparampil V. Scaria, Daming Zhu, Olga Muratova, Sara A. Healy
Publikováno v:
The Journal of Clinical Investigation
Background Vaccines that block human-to-mosquito Plasmodium transmission are needed for malaria eradication and clinical trials have targeted zygote antigen Pfs25 for decades. We reported that a Pfs25 protein-protein conjugate vaccine formulated in a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::627e5a134b853bfccd39a5603bbf518a
https://doi.org/10.1172/jci146221
https://doi.org/10.1172/jci146221
Autor:
Robert T. Bailer, Maria Burgos Florez, Lucio Gama, Sung-Youl Ko, Zonghui Hu, Cynthia S. Hendel, Ro Shauna S Rothwell, Amarendra Pegu, Lily Zhang, Brenda Larkin, Katherine V. Houser, Jennifer Cunningham, Martin R. Gaudinski, Olga Vasilenko, Sandra Sitar, Julie E. Ledgerwood, Nicole A. Doria-Rose, Kathy Zephir, Preeti Apte, KC Cheng, William Whalen, Renunda Hicks, Richard A. Koup, Margarita M. Gomez Lorenzo, Floreliz Mendoza, Xiaolin Wang, Cristina Carter, LaSonji A. Holman, Young Do Kwon, Frank J. Arnold, Hope DeCederfelt, Grace L. Chen, Aryan M. Namboodiri, Peter D. Kwong, Kevin Carlton, Adrian B. McDermott, Joseph P. Casazza, Bob C. Lin, Nina M. Berkowitz, Nilusha Jayasinghe, Laura Novik, Catina R. Boyd, Edmund V. Capparelli, Carol Levinson, Galina Yamshchikov, Cora Trelles Cartagena, Carolyn M. Laurencot, Jason G. D. Gall, Michelle Conan-Cibotti, Sarah H. Plummer, Yunda Huang, Abidemi Ola, Pamela Costner, Ingelise J. Gordon, Janardan P. Pandey, Richard M. Schwartz, Judy Stein, Pernell Williams, Florence Kaltovich, Jamie G. Saunders, Iris Pittman, Milalynn Victorino, John R. Mascola, Barney S. Graham
Publikováno v:
The lancet. HIV. 6(10)
Summary Background Human monoclonal antibodies that potently and broadly neutralise HIV-1 are under development to prevent and treat HIV-1 infection. In this phase 1 clinical trial we aimed to determine the safety, tolerability, and pharmacokinetic p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b775455c935479255ba3131295566fc
https://pubmed.ncbi.nlm.nih.gov/31473166
https://pubmed.ncbi.nlm.nih.gov/31473166
Autor:
Martin R Gaudinski, Katherine V Houser, Kaitlyn M Morabito, Zonghui Hu, Galina Yamshchikov, Ro Shauna Rothwell, Nina Berkowitz, Floreliz Mendoza, Jamie G Saunders, Laura Novik, Cynthia S Hendel, LaSonji A Holman, Ingelise J Gordon, Josephine H Cox, Srilatha Edupuganti, Monica A McArthur, Nadine G Rouphael, Kirsten E Lyke, Ginny E Cummings, Sandra Sitar, Robert T Bailer, Bryant M Foreman, Katherine Burgomaster, Rebecca S Pelc, David N Gordon, Christina R DeMaso, Kimberly A Dowd, Carolyn Laurencot, Richard M Schwartz, John R Mascola, Barney S Graham, Theodore C Pierson, Julie E Ledgerwood, Grace L Chen, Sarah Plummer, Pamela Costner, Kathryn Zephir, Joseph Casazza, Abidemi Ola, Milalynn Victorino, Carol Levinson, William Whalen, Xiaolin Wang, Jennifer Cunningham, Olga Vasilenko, Maria Burgos Florez, Somia Hickman, Iris Pittman, Lam Le, Brenda Larkin, Charla Andrews, Preeti Apte, Renunda Hicks, Cora Trelles Cartagena, Pernell Williams, Catina R Boyd, Michelle Conan-Cibotti, Judy Stein, Florence Kaltovich, Hope DeCederfelt, Stacey McAdams, Phyllis Renehan, Wilbur Chen, Nancy Greenberg, Nancy Wymer, Linda Wadsworth, Melissa Billington, Toni Robinson, Colleen Boyce, Faith Pa'ahana Brown, Lisa Chrisley, Alyson Kwon, Prashant Patel, Panagoita Kominou, Brenda Dorsey, Staci Eddington, Shinyi Telscher, Myoughee Lee, Regina Mosely, April Ross, Geoffrey Ford, Briyana Domjahn, Jianguo Xu, Allison Beck, Rebecca Fineman, Shiela Heeke, Jean Winter, Shashi Nagar, Colleen Kelley, Mark Mulligan
Publikováno v:
The Lancet
Summary Background The Zika virus epidemic and associated congenital infections have prompted rapid vaccine development. We assessed two new DNA vaccines expressing premembrane and envelope Zika virus structural proteins. Methods We did two phase 1,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bd672ef0d2113385a4e636916a6279f
https://pubmed.ncbi.nlm.nih.gov/29217377
https://pubmed.ncbi.nlm.nih.gov/29217377
Autor:
Andrew S, Ishizuka, Kirsten E, Lyke, Adam, DeZure, Andrea A, Berry, Thomas L, Richie, Floreliz H, Mendoza, Mary E, Enama, Ingelise J, Gordon, Lee-Jah, Chang, Uzma N, Sarwar, Kathryn L, Zephir, LaSonji A, Holman, Eric R, James, Peter F, Billingsley, Anusha, Gunasekera, Sumana, Chakravarty, Anita, Manoj, MingLin, Li, Adam J, Ruben, Tao, Li, Abraham G, Eappen, Richard E, Stafford, Natasha, K C, Tooba, Murshedkar, Hope, DeCederfelt, Sarah H, Plummer, Cynthia S, Hendel, Laura, Novik, Pamela J M, Costner, Jamie G, Saunders, Matthew B, Laurens, Christopher V, Plowe, Barbara, Flynn, William R, Whalen, J P, Todd, Jay, Noor, Srinivas, Rao, Kailan, Sierra-Davidson, Geoffrey M, Lynn, Judith E, Epstein, Margaret A, Kemp, Gary A, Fahle, Sebastian A, Mikolajczak, Matthew, Fishbaugher, Brandon K, Sack, Stefan H I, Kappe, Silas A, Davidson, Lindsey S, Garver, Niklas K, Björkström, Martha C, Nason, Barney S, Graham, Mario, Roederer, B Kim Lee, Sim, Stephen L, Hoffman, Julie E, Ledgerwood, Robert A, Seder
Publikováno v:
Nature medicine. 22(6)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5ad1dfd70edeebc696235ee5718145d9
https://pubmed.ncbi.nlm.nih.gov/27158907
https://pubmed.ncbi.nlm.nih.gov/27158907
Autor:
Sumana Chakravarty, Eric R. James, Tao Li, Kirsten E. Lyke, Abraham G. Eappen, Mario Roederer, Laura Novik, Adam Ruben, Uzma N. Sarwar, Anita Manoj, Sebastian A. Mikolajczak, Hope Decederfelt, Cynthia S. Hendel, Brandon K. Sack, Stefan H. I. Kappe, Pamela Costner, Matthew B. Laurens, Mary E. Enama, Adam DeZure, Niklas K. Björkström, Jay Noor, Lindsey S. Garver, Silas A. Davidson, Natasha K C, B. Kim Lee Sim, William R Whalen, Julie E. Ledgerwood, Stephen L. Hoffman, Barbara J. Flynn, Minglin Li, Andrew S. Ishizuka, Robert A. Seder, Martha Nason, Judith E. Epstein, Peter F. Billingsley, Lee-Jah Chang, Sarah H. Plummer, Ingelise J. Gordon, Christopher V. Plowe, Kailan Sierra-Davidson, Richard E. Stafford, Margaret A. Kemp, Barney S. Graham, Anusha Gunasekera, Kathryn L Zephir, Srinivas S. Rao, Thomas L. Richie, Tooba Murshedkar, LaSonji A. Holman, John Paul Todd, Floreliz Mendoza, Matthew Fishbaugher, Jamie G. Saunders, Andrea A. Berry, Gary A. Fahle, Geoffrey M. Lynn
Publikováno v:
Nature medicine. 22(6)
An attenuated Plasmodium falciparum (Pf) sporozoite (SPZ) vaccine, PfSPZ Vaccine, is highly protective against controlled human malaria infection (CHMI) 3 weeks after immunization, but the durability of protection is unknown. We assessed how vaccine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a718d82c493e141707776c75ccf0b084
https://pubmed.ncbi.nlm.nih.gov/27270781
https://pubmed.ncbi.nlm.nih.gov/27270781
Autor:
Mary E. Enama, Pamela Costner, Galina Yamshchikov, Ingelise J. Gordon, Michelle Conan-Cibotti, Phyllis Renehan, Meghan Kunchai, Cynthia S. Hendel, Alisha Kabadi, Floreliz Mendoza, LaSonji A. Holman, Donald M. Poretz, Jamie G. Saunders, Zonghui Hu, Julie E. Ledgerwood, Laura Novik, Robert T. Bailer, Uzma N. Sarwar, John R. Mascola, Barry A. Eagel, Judith Starling, Sarah H. Plummer, Olga Vasilenko, Sandra Sitar, Kathryn L Zephir, Hope Decederfelt, Barney S. Graham, Sheryl Young, Diane Johnson, Joseph P. Casazza, Richard N. Jones, Richard A. Koup, Ly Diep, Charla Andrews, Brenda Larkin
Publikováno v:
Contemporary clinical trials. 44
Annual influenza vaccination reduces the risks of influenza when the vaccines are well matched to circulating strains, but development of an approach that induces broader and more durable immune responses would be beneficial. We conducted two compani
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0a78e2d7ebe87a5bf46de899d7f0804
https://pubmed.ncbi.nlm.nih.gov/26275339
https://pubmed.ncbi.nlm.nih.gov/26275339
Publikováno v:
American Journal of Health-System Pharmacy. 54:1604-1610
Policies and procedures for handling gene-transfer products at the National Institutes of Health (NIH) Clinical Center pharmacy department are described. The pharmacy at the Clinical Center is responsible for handling in vivo gene-transfer delivery s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d387199946a0c5391e859910572698e
https://doi.org/10.1093/ajhp/54.14.1604
https://doi.org/10.1093/ajhp/54.14.1604